in the meaning of the United States Private Securities
Litigation Reform Act of 1995 ("PSLRA") and which may be based on or
include assumptions concerning KV's operations, future results and
prospects. Such statements may be identified by the use of words like
"plans", "expect", "aim", "believe", "projects", "anticipates", "commit",
"intend", "estimate", "will", "should", "could" and other expressions that
indicate future events and trends.
All statements that address expectations or projections about the
future, including without limitation, statements about the Company's
strategy for growth, product development, product launches, regulatory
approvals, market position, market share increases, acquisitions, revenues,
expenditures and other financial results, and expectations and beliefs
pertaining to the announced Audit Committee inquiry or any allegations of
misconduct that are the subject of such inquiry, are forward-looking
statements.
All forward-looking statements are based on current expectations and
are subject to risk and uncertainties. In connection with the "safe harbor"
provisions, KV provides the following cautionary statements identifying
important economic, political and technology factors, which among others,
could cause actual results or events to differ materially from those set
forth or implied by the forward-looking statements and related assumptions.
Such factors include (but are not limited to) the following: (1)
changes in the current and future business environment, including interest
rates and capital and consumer spending; (2) the difficulty of predicting
FDA approvals, including timing, and that any period of exclusivity may not
be realized; (3) acceptance and demand for new pharmaceutical products; (4)
the impact of competitive products and pricing, including as a result of
so-called authorized-generic drugs; (5) new product development and launch,
including the possibility that any product launch may be delayed or tha
'/>"/>
SOURCE KV Pharmaceutical Company Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Related medicine news :1.
Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business2.
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference3.
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)4.
Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet5.
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)6.
National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership7.
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)8.
Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma9.
Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 200710.
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences11.
Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance